42116-56-3

Usage

Uses

Used in Pharmaceutical Industry:
tert-butyl 3-hydrazinyl-3-oxopropylcarbamate is used as a synthetic intermediate for the production of GABAA receptor agonists. These agonists are important in the treatment of various disorders, as they modulate the activity of the GABAA receptors, which play a crucial role in the central nervous system. The agonists help in managing conditions such as anxiety, insomnia, and epilepsy by enhancing the inhibitory effects of GABA in the brain.
Used in Chemical Synthesis:
In the field of organic chemistry, tert-butyl 3-hydrazinyl-3-oxopropylcarbamate is utilized as a building block for the synthesis of complex organic molecules. Its reactivity and functional groups make it a valuable component in the creation of pharmaceuticals, agrochemicals, and other specialty chemicals. The hydrazide group can participate in various chemical reactions, such as condensation, cyclization, and reduction, enabling the formation of diverse molecular structures with potential applications in different industries.

Upstream product

• 3303-84-2 3-(tert-butyloxycarbonylamino)propionic acid 
• 88574-53-2 3-tert-butoxycarbonylamino-propionic acid ethyl ester 
• 42116-55-2 methyl 3-tert-butoxycarbonylaminopropionate 
• 1070-19-5 N-(tert-butyloxycarbonyl) azide 
• 4138-35-6 methyl 3-aminopropanoate 

Downstream Products

• 843619-52-3 [2-(5-thioxo-4,5-dihydro-[1,3,4]oxadiazol-2-yl)-ethyl]-carbamic acid tert-butyl ester 
• 1188405-98-2 C₂₈H₃₈N₆O₆ 

Relevant academic research and scientific papers

Cascade reactions for constructing heterocycles containing a pyrimidino-pyrazino-pyrimidine core using 1,2,4-triazole scaffolds

The regioselective cyclocondensation of aminoethyl-1,2,4-triazoles and glyoxal provides pentacyclic heterocycles in which two 7,8-dihydro-5H-6λ2-[1,2,4]triazolo[1,5-c]pyrimidine systems are connected through CH(OH) bridges generating a central piperazine-2,5-diol ring. The structure of the new compounds was elucidated based on 1H, 13C and 15N NMR spectroscopic methods. The molecular structure of the parent compound generated from aminoethyl-1,2,4-triazole was established by single crystal X-ray diffraction.

?-LACTAMASE INHIBITOR AND USE THEREOF

Provided are a β-lactamase inhibitor of formula (I), or an ester, a stereoisomer or a pharmaceutically acceptable salt thereof, and a method of preparing the same. Further provided is a pharmaceutical composition comprising the β-lactamase inhibitor of formula (I), or the ester, the stereoisomer or pharmaceutically acceptable salt thereof. In addition, the present invention relates to a method for treating diseases caused by bacterial infection, which comprises administering the β-lactamase inhibitor of formula (I), or the ester, the stereoisomer or the pharmaceutically acceptable salt thereof to a patient or a subject in need.

Synthesis of macrocycles containing 1,3,4-oxadiazole and pyridine moieties

A series of peptide-like 25-28 membered macrocycles containing 1,3,4-oxadiazoles and pyridines bearing a chiral center scaffold have been synthesized by using known coupling reagents and common protecting groups. The yield of the purified macrocycles was poor on an average, yet it seems to be independent of amino acid substitution or stereochemistry. These macrocycles represent a new class of structures for further development and for future application in high-throughput screening against a variety of biological targets.

Synthesis of GABAA receptor agonists and evaluation of their α-subunit selectivity and orientation in the GABA binding site

Drugs used to treat various disorders target GABAA receptors. To develop α subunit selective compounds, we synthesized 5-(4-piperidyl)-3-isoxazolol (4-PIOL) derivatives. The 3-isoxazolol moiety was substituted by 1,3,5-oxadiazol-2-one, 1,3,5-oxadiazol-2-thione, and substituted 1,2,4-triazol-3-ol heterocycles with modifications to the basic piperidine substituent as well as substituents without basic nitrogen. Compounds were screened by [3H]muscimol binding and in patch-clamp experiments with heterologously expressed GABAA αiβ 3γ2 receptors (i = 1-6). The effects of 5-aminomethyl-3H-[1,3,4]oxadiazol-2-one 5d were comparable to GABA for all α subunit isoforms. 5-piperidin-4-yl-3H-[1,3,4]oxadiazol-2-one 5a and 5-piperidin-4-yl-3H-[1,3,4]oxadiazol-2-thione 6a were weak agonists at α2-, α3-, and α5-containing receptors. When coapplied with GABA, they were antagonistic in α2-, α4-, and α6-containing receptors and potentiated α3-containing receptors. 6a protected GABA binding site cysteine-substitution mutants α1F64C and α1S68C from reacting with methanethiosulfonate-ethylsulfonate. 6a specifically covalently modified the α1R66C thiol, in the GABA binding site, through its oxadiazolethione sulfur. These results demonstrate the feasibility of synthesizing α subtype selective GABA mimetic drugs.

TRIAZOLE DERIVATIVE

A compound represented by the formula (I) below or a pharmaceutically acceptable salt thereof has an effect of inhibiting binding between SIP and its receptor Edg-1(S1P1), and is useful as a pharmaceutical product. [where A represents a sulfur

CARBOXAMIDE DERIVATIVE

An SGLT inhibitor comprising a compound of the formula: (|) wherein the ring A is an optionally substituted ring; R1 is an optionally substituted hydrocarbon group, etc.; each of R2 and R3 independently is a hydrogen atom, an optionally substituted hydrocarbon group, etc.; R4 is an optionally substituted hydrocarbon group, etc.; and X is a bivalent chain group whose main chain consists of 1 to 6 atoms. This SGLT inhibitor is useful as a preventive/therapeutic agent for diabetes mellitus, obesity, hypertension, hyperlipemia, etc.